Neogenomics
Depends
Confidence: Medium
NeoGenomics is a publicly traded cancer-diagnostics lab, not software.
New check
Comparison
Neogenomics and Quest Diagnostics | Quest Corporate both land on Depends.
NeoGenomics is a publicly traded cancer-diagnostics lab, not software.
A fit only if you're a large employer or health system procuring lab testing at negotiated scale.
| Compare | ||
|---|---|---|
| Verdict | Depends | Depends |
| Best for | Oncology practices needing specialty pathology | Large employers running drug & wellness screening |
| Who it's not for | Anyone shopping for software. This is a lab, not a SaaS tool | Anyone shopping for software. This is a corporate site, not a product |
| Privacy | No known public vulnerabilities found in the sources reviewed.15 | Known 2019 breach exposed ~12M customers via a billing vendor; incident trackers list additional entries with no public detail. |
| Support quality | Only truncated anecdotes; no support data | No buyer-side support evidence |
| Public sentiment | Evidence is mostly employee-side. 498 Glassdoor and 178 Indeed reviews with mixed sentiment.¹ | Evidence is thin and mostly employee- or patient-side: mixed corporate-culture reviews and complaints about lab access; no buyer reviews found. |
| Biggest gotcha | No published prices. Billing runs through insurance and negotiated client contracts; expect opaque invoices13 | The 2019 breach came via a third-party billing vendor, vendor risk persists. |